A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
Trial details
- Registry ID
- NCT05002127
- Phase
- Phase 2, Phase 3
The FDA approved Paclitaxel (Nov-Onxol, Onxol, Navaplus, Taxol) on 29 Dec 1992.
Drug identity checked against registry records
Also recorded as Nov-Onxol, Onxol, Navaplus, Taxol; Taxol; Weekly Paclitaxel
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 1992-12-29Day | Paclitaxel | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA020262", "applicant_as_listed_by_fda": "HQ SPCLT PHARMA", "brand_names": ["TAXOL"], "active_ingredients": ["PACLITAXEL"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "19921229", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |